Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis

Company Overview

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: 303.60 to 320
• 50-Day Range: 281 to 420
• 52-Week Range: 270 to 1,276
• Volume: 31,809 shs
• Average Volume: 13,799 shs
• Market Capitalization: £11.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HEMO Stock Analysis - Frequently Asked Questions

How have HEMO shares performed this year?

Hemogenyx Pharmaceuticals' stock was trading at GBX 402 at the start of the year. Since then, HEMO stock has decreased by 21.0% and is now trading at GBX 317.50.
View the best growth stocks for 2025 here.

How were Hemogenyx Pharmaceuticals' earnings last quarter?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) posted its earnings results on Wednesday, September, 30th. The company reported ($0.20) earnings per share (EPS) for the quarter.

How do I buy shares of Hemogenyx Pharmaceuticals?

Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Hemogenyx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA).

Company Calendar

• Last Earnings: 9/30/2020
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:HEMO
• Previous Symbol: LON:SILF
• CUSIP: N/A
• CIK: N/A
• Web: silverfalconplc.com
• Phone: 44 79 0917 7311
• Fax: N/A
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-6,890.55
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -80.66%
• Return on Assets: -37.79%

Debt

• Debt-to-Equity Ratio: 90.87
• Current Ratio: 4.38
• Quick Ratio: 6.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 155.26 per share
• Price / Cash Flow: 2.05
• Book Value: GBX 0.25 per share
• Price / Book: 1,288.77

Miscellaneous

• Outstanding Shares: 3,564,489
• Free Float: N/A
• Market Cap: £11.32 million
• Optionable: Not Optionable
• Beta: 3.14